Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

被引：2
|
作者：
Starodub, A.
Cohn, A. L.
Arrowood, C.
Haley, S.
Morse, M.
Uronis, H. E.
Blobe, G. C.
Hsu, S. D.
Zafar, Y.
Hurwitz, H.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
513
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
  • [32] A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer
    Sehgal, Rajesh
    Lembersky, Barry C.
    Rajasenan, Kiran K.
    Crandall, Theodore L.
    Balaban, Edward P.
    Pinkerton, Richard A.
    Kane, Patrick
    Schmotzer, Amy
    Zeh, Herbert
    Potter, Douglas M.
    Ramanathan, Ramesh K.
    CLINICAL COLORECTAL CANCER, 2011, 10 (02) : 117 - 120
  • [33] A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer
    Faris, Jason Edward
    Blaszkowsky, Lawrence Scott
    Abrams, Thomas Adam
    Enzinger, Peter C.
    Hezel, Aram F.
    Wolpin, Brian M.
    Ryan, David P.
    Kwak, Eunice Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [34] A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer.
    Bendell, J. C.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Schaffer, S.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 156S - 156S
  • [35] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [36] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
  • [37] A PHASE II TRIAL OF GEMCITABINE IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE IN PREVIOUSLY UNTREATED METASETATIC OR RECURRENT PANCREATIC CANCER
    Sym, S. J.
    Hong, J.
    Jung, M.
    Koo, Y. S.
    Park, Y. H.
    Kim, K. K.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Shin, D. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 152 - 152
  • [38] Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
    Oh, Do-Youn
    Doi, Toshihiko
    Shirao, Kuniaki
    Lee, Keun-Wook
    Park, Sook Ryun
    Chen, Ying
    Yang, Liqiang
    Valota, Olga
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 687 - 696
  • [39] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Naoki Takahashi
    Satoru Iwasa
    Masaru Fukahori
    Kazuki Sudo
    Yusuke Sasaki
    Hirokazu Shoji
    Yoshitaka Honma
    Natsuko Tsuda Okita
    Atsuo Takashima
    Tetsuya Hamaguchi
    Narikazu Boku
    Yasuhiro Shimada
    Kazufumi Honda
    Tesshi Yamada
    Yasuhide Yamada
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 567 - 575
  • [40] A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
    Takahashi, Naoki
    Iwasa, Satoru
    Fukahori, Masaru
    Sudo, Kazuki
    Sasaki, Yusuke
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko Tsuda
    Takashima, Atsuo
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Shimada, Yasuhiro
    Honda, Kazufumi
    Yamada, Tesshi
    Yamada, Yasuhide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 567 - 575
12345